[ET Net News Agency, 6 September 2018] Sihuan Pharmaceutical (00460) said the
long-acting insulin analogue degludec developed by the group has been granted approval for
clinical trials from China Food and Drug Administration and has commenced pre-clinical
preparation.
Recombinant insulin degludec is an ultra long-acting insulin analogue intended to treat
type 2 diabetes in adult patients. It is demonstrated in previous clinical studies that
the drug has ultra-long glucose-lowering effect and stable pharmacokinetic profiles,
leading to persistent, stable and long-lasting glucose lowering effects, which reduce the
risk of hypoglycemia especially for the occurrence of nocturnal hypoglycemia. (SC)